Safety of Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis During the Open-label Extension Period of the Phase 3 MANDARA Study
C34. BIOLOGIC THERAPY IN THE FIGHT AGAINST ASTHMA AND ALLERGIC INFLAMMATION | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5358-A5358